SBI Securities’s Benitec Biopharma BNTC Stock Holding History

SBI Securities’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$80	Buy	+8	New	+$98	﹤0.01%	3638
2025 Q4	–	Sell	-1	Closed	-$14	–	4047
2025 Q3	$14	Buy	+1	New	+$13	﹤0.01%	3974

Other funds holding BNTC

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

SBI Securities's BNTC Position: Q3 2026 in Review

SBI Securities opened a new position in Benitec Biopharma (BNTC) in Q3 2026: 8 shares worth $80. The stake represents ﹤0.01% of the portfolio and ranks #3638 among its holdings. This is a return to the name: SBI Securities previously reported a position in BNTC as recently as Q3 2025.

SBI Securities first reported a position in BNTC in Q3 2025 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold BNTC as of Q3 2026.

SBI Securities held 8 shares of Benitec Biopharma worth $80 as of Q3 2026.
Benitec Biopharma was a new SBI Securities position in Q3 2026.
Benitec Biopharma made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3638 holding.
SBI Securities first reported a position in Benitec Biopharma in Q3 2025 and has held it in 2 quarters since.
7 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.